Mesoblast enrolls 300th patient in Phase 3 back pain trial of rexlemestrocel-L
The company said commercial manufacturing is underway in parallel while it awaits results expected in mid-2027.
SEC filing
Latest
Tuesday, July 14
Cardiol's Phase II pericarditis data published in JAHA as Phase III MAVERIC nears full enrollment
Cardiol Therapeutics said the peer-reviewed publication supports its ongoing pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis.
SEC filing
Ligand closes $739 million acquisition of XOMA Royalty
The deal adds seven marketed royalty products and more than 100 development-stage assets to Ligand's portfolio.
SEC filing
CervoMed presents new neflamapimod data at AAIC, backs 50 mg dose for DLB Phase 3
New biomarker, imaging and dosing analyses from the Phase 2b RewinD-LB trial support a 50 mg three-times-daily dose for a planned Phase 3 study in dementia with Lewy bodies.
SEC filing (2)
FDA approves supplement 7 for Eli Lilly's Retevmo (selpercatinib)
The agency cleared an efficacy-related labeling update for the RET inhibitor, with a new label dated July 29, 2026.
Drugs@FDA
FDA approves efficacy supplement for Eli Lilly's Retevmo (selpercatinib)
The agency signed off on supplement 17 to Retevmo's original approval, with a new label dated July 29, 2026.
Drugs@FDA, SEC filing (2)
Propanc Biopharma board member departs, accountant Carlo Campiciano appointed to replace her
Annie Van Broekhoven retired from Propanc's board effective July 8, 2026, and the board named Carlo Campiciano to fill the vacancy.
SEC filing
Alto Neuroscience prices $93.9 million stock offering to fund ALTO-207 trial
The company will use proceeds to expand development of ALTO-207 for treatment-resistant depression, including an additional Phase 3 trial.
SEC filing
Attovia Therapeutics files S-1 for IPO on Nasdaq under ticker ATTO
The clinical-stage biotech disclosed $255.8 million raised to date as it seeks public funding to advance three ATTOBODY pipeline candidates.
SEC filing
Alto Neuroscience prices $100 million offering, plans Phase 3 trial of ALTO-207
The company priced 3,776,436 shares at $26.48 each and will direct proceeds toward an additional Phase 3 trial of ALTO-207 for treatment resistant depression.
SEC filing
Longeveron names Marie Washburn as CFO, revises CEO pay, grants Executive Chairman equity
Three July 2026 filings detail Longeveron's finance leadership change, an amended CEO letter agreement, and special equity awards for its Executive Chairman.
SEC filing (3)
Spero licenses anti-CD40L antibody SP001 from Innovent in deal worth up to $1.1 billion
Spero Therapeutics gains global rights outside Greater China to SP001 (IBI355) for IgG4-related disease and other immune conditions, backed by a separate $105 million royalty financing.
SEC filing
Jaguar Health's Napo signs new crofelemer supply deal with Alivus after 2020 pact expired
The new agreement, dated July 9, 2026, runs through March 31, 2029 and replaces the prior manufacturing deal that lapsed on March 31, 2026.
SEC filing
Braveheart Bio files for IPO, plans two global Phase 3 trials for HCM drug BHB-1893
The clinical-stage company has raised about $185 million to date and plans to start its oHCM Phase 3 trial in the second half of 2026, with an nHCM trial to follow in early 2027.
SEC filing
Monday, July 13
Q32 Bio reports positive Phase 2a bempikibart results in alopecia areata
Part B of the SIGNAL-AA trial hit its primary endpoint with a 35.3% mean SALT score reduction, and Q32 disclosed it paid off its SVB loan.
SEC filing (2)
Immutep reports 30.9-month median survival in Phase I NSCLC combination trial
The company also disclosed differing immune activation data from the discontinued TACTI-004 Phase III study, with root cause findings due in Q3 CY2026.
SEC filing
Edgewise completes sevasemten sale to Servier, sharpens cardiovascular focus
The July 10, 2026 closing brings Edgewise $1.55 billion upfront plus up to $1.1 billion in milestones, funding EDG-7500 through potential approval.
SEC filing
FDA approves efficacy-related supplement for Eli Lilly's Verzenio
The agency approved supplement 21 for the abemaciclib tablet, an efficacy-type submission, with the approval dated July 13, 2026.
Drugs@FDA
Clearmind reports investigator update on CMND-100 trial for alcohol use disorder
Yale and Johns Hopkins investigators described an early safety profile with no notable adverse effects in the ongoing Phase I/IIa study of MEAI.
SEC filing
IGC Pharma discloses updated CALMA Phase 2 data in investor presentation
The company furnished a July 2026 investor deck with interim Alzheimer's agitation trial results, but cautioned the data are preliminary and blinded.
SEC filing
BioNTech recruiting for BNT168 HIV vaccine Phase I/II trial
Sanuwave preliminary Q2 2026 revenue tops raised guidance range
The wound care device maker said revenue of $9.6 to $9.8 million beat the high end of its revised guidance issued in June, even as capital sales faced pressure.
SEC filing
Revelation Biosciences adopts stockholder rights plan
The San Diego biotech's board issued a "poison pill" triggered by 10% ownership stakes, with rights expiring in one to three years absent redemption.
SEC filing
Pliant Therapeutics expands board, adds two independent directors
Effective July 9, 2026, Pliant increased its board to nine seats and named Robert Iannone and Flavia Borellini as new directors.
SEC filing
Amphastar expands board, adds Anthony Pierce as director
Amphastar Pharmaceuticals' board grew to eleven seats on July 9, 2026, with Anthony Pierce joining as a Class III director through 2028.
SEC filing
OmniAb names Amechi Nwachuku as Chief Operating Officer
The appointment took effect July 13, 2026, with a base salary of $445,000 and stock options for 800,000 shares.
SEC filing
Alto Neuroscience plans added Phase 3 trial for depression drug ALTO-207
The company disclosed plans to expand development of ALTO-207 alongside a preliminary cash update as of June 30, 2026.
SEC filing
Lakefront board member Fontoura resigns after Sanofi names him R&D chief
Paulo Fontoura steps down from Lakefront Biotherapeutics' board following his appointment to a top research role at Sanofi.
SEC filing
MBX Biosciences registers Phase 3 trial of canvuparatide for hypoparathyroidism
Tarsus Pharmaceuticals' chief commercial officer to depart July 15
Aziz Mottiwala is leaving the company to become CEO of a public medical device company, according to a filing dated July 13, 2026.
SEC filing
Hutchmed completes Phase 1 drug interaction study for HMPL-453 tartrate tablets
AbbVie updates registry record NCT07697456: recruiting
Agenus secures up to $340 million to fund Phase 3 ROBBIN trial in MSS colon cancer
The private placement includes $85 million upfront and up to $255 million in warrant proceeds, while Agenus drops funding for its BATTMAN trial in late-line disease.
SEC filing
Penn Medicine registers PICSTAT pilot testing CD8 PET imaging with Iovance's lifileucel
VCU registers END-EXT natural history study for myotonic dystrophy type 1; Dyne, Vertex collaborate
MBX Biosciences names Steven Hoerter CEO as Kent Hawryluk departs
The company disclosed a leadership transition effective July 13, 2026, with CFO John Smither also elevated from interim to permanent status.
SEC filing
Matinas to combine with GH Power, sell drug unit MAT2203 to Azurity
The biopharma company plans to become a clean energy business through a merger while divesting its lead antifungal candidate in a separate deal worth up to $21.5 million.
SEC filing
Ocugen signs term sheet to license OCU400 for MENA region
Roots Pharmaceutical and partner Al-Dhow International Holding gain exclusive rights to Ocugen's retinitis pigmentosa gene therapy across the Middle East and North Africa under a binding term sheet.
SEC filing
Amicus reports FY2025 results as BioMarin merger deal proceeds
Amicus Therapeutics posted 2025 financials showing improved net product sales and a narrower net loss, while confirming terms of its pending acquisition by BioMarin.
SEC filing
FDA approves Teva's generic eltrombopag olamine tablets in three strengths
Friday, July 10
Crinetics discloses non-compete deals with executives tied to Vertex merger
The agreements, signed July 6, 2026, restrict Crinetics' CEO, CFO, CSO, and chief commercial officer from competing for a year after the deal closes.
SEC filing
Traws Pharma files prospectus supplement for up to $5.58 million at-the-market stock sale
The company disclosed a clinical hold on its bird flu drug and a going concern warning while setting terms for a Citizens Capital Markets equity sale program.
SEC filing
Abbott registers VOYAGER CE trial for Encantor TAVI System in aortic stenosis
Cellectar shareholders back share plan increase and warrant exercise vote
At its July 7, 2026 annual meeting, Cellectar Biosciences investors approved a 2,000,000-share increase to the equity incentive plan and a proposal allowing exercise of warrants for up to 39.6 million shares.
SEC filing
Cue Biopharma raises $50 million in private placement of stock and warrants
The financing, set to close July 13, 2026, was backed by Cormorant Asset Management and new investor Columbia Threadneedle Investments.
SEC filing
Decoy Therapeutics files S-1 to register 3.77 million shares from private placement warrants
The Houston biotech, formerly Salarius Pharmaceuticals, seeks to register shares underlying warrants issued in a $3.5 million private placement that closed June 29, 2026.
SEC filing
Apnimed files for IPO as FDA reviews Oxnimbi NDA for sleep apnea
The company disclosed FDA feedback questioning whether its Phase 3 data show a clinically meaningful benefit, even as it seeks Nasdaq listing under "APMD."
SEC filing